BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 25240597)

  • 1. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
    Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH
    ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
    Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
    Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
    Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
    [No Abstract]   [Full Text] [Related]  

  • 7. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
    Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
    Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
    J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
    Ma Z; Cai S; Xiong Q; Liu W; Xia H; Zhu Z; Huang Z; Yan X; Wang Q
    Apoptosis; 2022 Feb; 27(1-2):80-89. PubMed ID: 35037107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
    Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
    Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
    Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
    Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
    [No Abstract]   [Full Text] [Related]  

  • 18. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J
    BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.